VERAXA Biotech (NASDAQ: VRXA) announced the initiation of cell line development for its lead BiTAC(R) T-cell engager (BiTAC-TCE) program through a collaboration with ATUM. The partnership will apply ATUM's Leap-In Transposase(R) technology to generate stable clonal cell lines supporting IND/CTA-enabling activities and future clinical development. This follows encouraging preclinical data presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting and is intended to support CMC development, including early process, analytical and formulation development, as well as the production of material for nonclinical studies.
VERAXA's BiTAC-TCE platform is designed to improve tumor selectivity by splitting the T-cell engager into two complementary precursors that activate only when both bind separate tumor targets on the same cell. The company believes this conditional “AND”-gated approach could reduce off-tumor toxicity associated with conventional T-cell engagers while maintaining anti-cancer activity, potentially enabling higher dosing and a broader therapeutic window. This innovative strategy addresses a key challenge in cancer immunotherapy: the balance between efficacy and safety.
The initiation of cell line development marks a critical step toward advancing the BiTAC program into the clinic. By leveraging ATUM's technology, VERAXA aims to accelerate the production of high-quality cell lines essential for manufacturing and nonclinical studies. For more information, the full press release is available at https://ibn.fm/FCIlk.
VERAXA Biotech is building a premier engine for the discovery and development of next-generation antibody-based therapeutics, including bispecific T cell engagers, bispecific ADCs, and other innovative formats. Powered by transformative technologies and guided by rigorous quality-by-design principles, the company is rapidly advancing its pipeline of ADCs and proprietary BiTAC formats into clinical development. VERAXA was founded on scientific breakthroughs made at the European Molecular Biology Laboratory (EMBL), a world-renowned institution known for pioneering life science research and cutting-edge technology. BiTAC(R) is a registered trademark of VERAXA Biotech GmbH.
This announcement underscores VERAXA's commitment to developing safer and more effective cancer therapies. The potential of the BiTAC platform to improve therapeutic index could have significant implications for patients, offering a new option that may reduce severe side effects commonly associated with T-cell engagers. As the company progresses toward IND-enabling studies, the successful development of stable cell lines will be crucial for manufacturing consistency and regulatory approval. Further updates and news regarding VRXA are available in the company’s newsroom at https://ibn.fm/VRXA.
